Run­ning be­hind Bris­tol My­ers and J&J, Bay­er inch­es for­ward in the next-gen blood thin­ner race

Over the week­end, Bay­er took an in­ter­me­di­ate step in its quest to chase down Bris­tol My­ers Squibb and J&J in the next-gen­er­a­tion blood thin­ner race.

In a Lancet pa­per pub­lished Sun­day de­tail­ing a Phase II safe­ty and dose-find­ing study, Bay­er’s ex­per­i­men­tal drug asun­dex­i­an re­duced the num­ber of bleed­ing events by 67% com­pared to Eliquis, a stan­dard of care. Bay­er’s next steps are to wrap up an­oth­er Phase II, fi­nal­ize the dose and push it in­to a Phase III study, like­ly by the end of this year, lead au­thor Manesh Pa­tel told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER